Biocartis US Inc.
Itasca, IL Biocartis US Inc.
- UEI
- RY27EUE8U9B7
- CAGE
- 8FD63
- Primary NAICS
- 334516 Analytical Laboratory Instrument Manufacturing
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- NAICS codes registered in SAM.gov
- SAM.gov registration date
- Physical address
- 2 Pierce Pl #1510, Itasca, IL 60143, USA
- Website
- biocartis.com
- Founded
- 2007
- Employees
- 251-1K
- Estimated annual revenue
- $50M-$100M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Life Sciences Tools & Services
- SIC code
- 38 Instruments & Related Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| MSI testing reagent cartridges on reagent rental | Veterans Integrated Service Network 22 | $76,050 | |
| Biocartis idylla service agreement for the charles george VA medical center in asheville, NC. | Veterans Integrated Service Network 6 | $14,220 | |
| MSI testing reagent cartridge | Veterans Integrated Service Network 22 | $62,361 | |
| FY25 biocartis service agreement. | Veterans Integrated Service Network 6 | $14,220 | |
| MSI testing reagents | Veterans Integrated Service Network 22 | $60,479 |
About Biocartis US Inc.
Biocartis US Inc., a foreign-owned for-profit company headquartered in Itasca, Illinois, supplies molecular diagnostic testing platforms and reagents to the Veterans Health Administration as a prime contractor exclusively in full-and-open, unrestricted commercial products procurements with no set-aside usage. The vendor operates across 100% of its recent federal footprint as prime contractor on purchase orders and definitive contracts, with zero subcontract engagement.
Biocartis's federal capability portfolio centers on the Idylla automated molecular diagnostic platform and consumable reagent cartridges for cancer diagnostics, with primary focus on microsatellite instability (MSI) testing and EGFR assays for rapid tumor classification. Representative work includes a $403,764 five-year definitive contract awarded by Veterans Integrated Service Network 22 in May 2026 for MSI testing reagent cartridges on a reagent rental basis supporting the VA Greater Los Angeles Healthcare System's Pathology and Laboratory Medicine department, a $247,199.70 purchase order from VISN 16 (July 2023–June 2024) for Idylla molecular diagnostic services delivered from Jersey City, New Jersey, and a $441,828.09 purchase order from VISN 22 (August 2021–August 2026) for Idylla instruments, EGFR assays, and related supplies. The MSI assay capabilities detect mutations across seven specific loci (ACVR2A, BTBD7, DIDO1, MRE11, RYR3, SEC31A, and SULF2) on FFPE tissue sections with results within approximately 150 minutes, and the Idylla platform performs rapid automated cancer diagnostics to support VA clinical and research operations.
Customer concentration is entirely within the Department of Veterans Affairs health system. VISN 22 (VA Greater Los Angeles Healthcare System) anchors the portfolio with five awards totaling $1.3 million in combined potential value, followed by VISN 6 (Charles George VA Medical Center in Asheville, North Carolina) with five awards totaling $267 thousand, and VISN 16, VISN 7, and VISN 10 with single awards each. All thirteen awards across the entire federal footprint derive from Veterans Health Administration networks.
Activity has been sporadic over the past five years (two awards in 2022, one in 2023, four in 2024, two in 2025, one in 2026), with combined potential value of $2 million and $1.2 million obligated to date (64% burn rate). Three awards totaling $621 thousand reach ultimate completion within the next twenty-four months and therefore present recompete windows. NAICS concentration splits between In-Vitro Diagnostic Substance Manufacturing (six awards) and Electronic and Precision Equipment Repair and Maintenance (three awards), with PSC codes tracking to In Vitro Diagnostic Substances (six awards) and Laboratory Equipment and Supplies (three awards).
Quick answers
What is Biocartis US Inc.'s UEI?
Biocartis US Inc.'s Unique Entity ID (UEI) in SAM.gov is RY27EUE8U9B7.
What is Biocartis US Inc.'s CAGE code?
Biocartis US Inc.'s CAGE code is 8FD63.
What is Biocartis US Inc.'s primary NAICS code?
Biocartis US Inc.'s primary NAICS code is 334516 (Analytical Laboratory Instrument Manufacturing).
Where is Biocartis US Inc. located?
Biocartis US Inc.'s physical address in SAM.gov is 2 Pierce Pl #1510, Itasca, IL 60143, USA.
Is Biocartis US Inc. registered in SAM.gov?
Yes. Biocartis US Inc.'s SAM.gov registration is active through July 27, 2027.
What is Biocartis US Inc.'s most recent federal award?
Biocartis US Inc.'s most recent federal contract award is MSI testing reagent cartridges on reagent rental (36C26226C0197), from Veterans Integrated Service Network 22, on May 22, 2026.
On GovTribe
See Biocartis US Inc.'s full federal record
- Federal contract awards
- IDV awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors